<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125947">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01738074</url>
  </required_header>
  <id_info>
    <org_study_id>HNCDC-001</org_study_id>
    <nct_id>NCT01738074</nct_id>
  </id_info>
  <brief_title>Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Disease Control and Prevention, Henan Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Disease Control and Prevention, Henan Province</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment and evaluation the rotavirus gastroenteritis prevention effect and severe
      rotavirus diarrhea reducing effectiveness of human body, which inoculate trivalent rotavirus
      genetic reassortment vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Antibody titer differences in serum</measure>
    <time_frame>4 weeks after full vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence differences of rotavirus diarrhea</measure>
    <time_frame>2 years after full vaccination.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10020</enrollment>
  <condition>Randomized</condition>
  <condition>Double-blind</condition>
  <condition>Placebo Control Design</condition>
  <arm_group>
    <arm_group_label>trivalent rotavirus genetic reassortment vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2ml of rotavirus genetic reassortment vaccine by mouth every month for three month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2ml of placebo by mouth every month for three month</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trivalent rotavirus genetic reassortment vaccine</intervention_name>
    <arm_group_label>trivalent rotavirus genetic reassortment vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 to 13 weeks aged healthy baby;

          -  Guardian volunteer to participate in the study and sign informed consent;

          -  have use thermometer as required and the ability to fill in the diary table;

          -  Subjects guardian can abide by the requirements of clinical research scheme;

          -  The past has not been vaccinated rotavirus vaccine;

          -  Normal term eutocia, birth weight up to standard;

          -  Axillary temperature is 37.0 â„ƒ or less.

        Exclusion Criteria:

          -  With allergy, convulsion, epilepsy, encephalopathy and spirit history or the family
             history;

          -  Be allergy to any ingredients in the vaccine;

          -  Known immunology function damage or low person;

          -  Immunosuppressant therapy Accepter;

          -  Suffering from congenital malformation and developmental disorder;

          -  Known or suspected also suffer from diseases including: digestive system disease,
             respiratory system disease, acute infection, mother or I have HIV infection,
             cardiovascular diseases, malignant tumor during treatment, skin disease;

          -  Inoculation other vaccine within 7 days.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>13 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 28, 2012</lastchanged_date>
  <firstreceived_date>November 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rotavirus</keyword>
  <keyword>trivalent genetic reassortment vaccine</keyword>
  <keyword>Phase three clinical trials</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
